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Background: The risk of Herpes Zoster (HZ) increases with age and various studies have also demonstrated an
increasing HZ incidence globally. Simultaneously, the global trend of an aging population has placed a greater
burden on the healthcare system. This study aims to estimate the potential burden of HZ over time accounting
for the increasing trends of both HZ incidence and global aging.
Methods: A recent systematic review on HZ incidence identified studies that evaluated the temporal effects of HZ
incidence. Data from the identified studies were extracted to estimate the trend of HZ incidence in the ≥65-year-old
age cohort. The incidence rates were estimated up to the year 2030 using two scenarios: a linear extrapolation and
a last observation carried forward. Three countries were chosen to perform the analysis on: Australia, Japan and the
United States.
Results: The incidence data from the three countries showed an average annual increase between 2.35 and 3.74%
over the time period of the studies selected. The elderly population for the US, Japan and Australia are expected to
increase by 55, 10 and 53% respectively by the year 2030 compared to the levels in 2015. Under the first scenario
between 2001 and 2030, the number of annual incident cases of HZ in those aged ≥65 years is expected to increase
by +343% (293,785 to 1,303,328), +176% (158,616 to 437,867) and +376% (18,105 to 86,268) in the US, Japan and
Australia respectively while those for the second scenario are +150%, +83% and +223% respectively. In the US alone,
the estimated annual cost of HZ-related cases in the ≥65 age cohort is approximately 4.74 Billion US$ in 2030.
Conclusions: The increasing incidence of HZ coupled with the demographic trends (i.e., aging population and greater
life expectancy) in many countries are likely to imply a rising economic burden of HZ on already constrained
healthcare budgets.
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Herpes Zoster (HZ) which is a reactivation of the latent
Varicella Zoster Virus (VZV) [1] is primarily a disease in
older adults and those with immunosuppressed condi-
tions or treatments [2]. A population based study
conducted by Yawn et al. using data between 1996 and
2005 in Olmsted County in the United States (US)
reported that the risk of HZ increases with age; from 4.7
per 1,000 in 50–59 year-old to 12.0 per 1,000 in
≥80 year-old [3]. The study also reported that HZ
complications, primarily Post-herpetic Neuralgia (PHN,
defined as pain lasting more than 90 days from the onset* Correspondence: lijoy.x.varghese@gsk.com
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50–59 year-old to 20.32% in ≥80 year-old [3]. An
extrapolation of the HZ incidence rate obtained from
the study to the 2005 US population, results in approxi-
mately 1 million new cases of HZ each year [3].
Various studies [4–11] have shown that the HZ incidence
increased in many countries, e.g. Australia, Canada, Japan
and the US. Hales et al. [11] estimated a 39% increase in
HZ incidence in the ≥65 year-old US Medicare insured
population between 1991 and 2010. Many reasons have
been cited for the increasing trend: (1) introduction of
routine varicella vaccination that reduces the exposure to
varicella and, thus, exogenous boosting [12, 13], (2) increas-
ing aging population and the associated prevalent chronic
diseases, (3) increasing prevalence of immunosuppressionle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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brought on by long-term stress and depression [14].
Simultaneously, the global trend of aging populations
presents a challenge to healthcare resources especially
with respect to diseases that impact the elderly such as
HZ. The National Institute on Aging estimates that by
2030, the world is likely to have over 1 billion people
aged ≥65. The oldest-old, i.e. the population aged ≥85, is
projected to grow by 46% between 2015 and 2030 com-
pared to of 28% for those aged ≥65 [15]. The increasing
HZ incidence coupled with the demographic trends (i.e.,
aging population and greater life expectancy) in many
countries would imply a greater economic burden of HZ
on already constrained healthcare budgets.
The objective of this study is to estimate the potential
burden of HZ (in terms of incident HZ cases) over time
by taking into consideration the trends of HZ incidence
and global aging. In this paper we focus on three coun-
tries for which we project the incident cases of HZ up to
2030 in the ≥65 age cohort; the US, Japan and Australia.
Methods
A recent systematic review by Kawai et al. on the global
HZ incidence identified 25 studies from 7 countries up to
December 2013 that presented the temporal trends of HZ
incidence [16]. We performed a search on PubMed to
identify more recent studies using a similar search strategy
[16]. We used Medical Subject Headings (MeSH) terms
for ‘herpes zoster’ in combination with the terms
‘incidence’ and ‘epidemiology’ from January 2014 to
November 2016. Studies that evaluated incidence of HZ
in children or adolescents and those that assessed the
rates of hospitalization arising from HZ were excluded.
Five new studies that reported temporal trends were
identified [17–21].
Data from the included studies were extracted to esti-
mate the annual HZ incidence (per 1,000 persons) in the
≥65 age cohort. If yearly incidence data was reported for
different age cohorts, an aggregate age-adjusted inci-
dence value for the ≥65 age cohort was estimated using
individual country demographic data obtained from the
respective national statistics databases. If the incidence
data was further reported based on gender, the age-
specific proportion of males to females obtained from
the corresponding national population databases was
used to arrive at an aggregate value.
To evaluate the future burden of HZ the incidence
rates for the various countries were projected up to the
year 2030 using the following two scenarios:
(a)Scenario 1 assumes that the linear trend modeled for
the corresponding country-specific annual HZ
incidence data is followed till the year 2030. A linear
curve was found to be the best-fit for the reportedyearly incidence reported in a majority of the data-
sets and consequently used for the studies
considered.
(b)Scenario 2 assumes a last observation carried
forward value, whereby the predicted incidence
based on the best fit linear curve of the last reported
year of each study is carried forward (i.e. assuming a
constant incidence value from the year of the
conclusion of the study till the year 2030). This
conservative scenario assumes that the incidence of
HZ reaches a maximum in the last year of the study
and the increase in HZ cases is solely an effect of
the demographic change in the country
To estimate the expected number of cases up to year
2030 for both scenarios, the corresponding predicted
value of incidence for each year was multiplied by the
projected population estimate for same year. Population
data and projections for the ≥65 year old age cohort up
to 2030 were obtained from United Nations World
Population Prospects: the 2015 revision [16]. The
medium fertility variant population projection was used
which takes into account a medium fertility, normal
mortality and normal international migration rates.
Although annual incidence rates were presented for 11
studies [4–7, 9, 11, 17, 19–22], we focused on three
studies as they reported the annual incidence data
specifically for the ≥65 age group while also reporting
incidence over a sufficiently long time period so as to
perform linear best fit curve. The studies used to esti-
mate the incidence rates were Leung et al. [6], Toyama
et al. [7] and MacIntyre et al. [4] which reported HZ in-
cidence rates for the US, Japan and Australia respectively
and was adjudged to present a reasonable picture of the
expected HZ burden in high-income country setting.
For the US, both Leung et al. [6] and Hales et al. [11]
evaluated the incidence rates for the ≥65 immunocom-
petent and overall population, but for our analysis we
conservatively considered the former (note the incidence
was consistently lower than rates reported in Hales
et al.) as the yearly incidence data was readily available
from the study Leung et al. [6] estimated the HZ inci-
dence using a retrospective cohort study of medical
claims data from the MarketScan (Truven Health
Analytics) databases for 1993–2006. The MarketScan
database is convenience sample that includes patient-
level information from over 100 self-insured employers,
state governments, hospitals, health insurance plans and
Medicare from all states in the United States of America.
HZ incidence (stratified by age and sex) was calculated
using all persons with a first outpatient service associ-
ated with a 053.xx code (HZ International Classification
of Diseases: ICD-9 code) as the numerator, and total
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Fig. 1 HZ incidence and trends in the Australia (AU), Japan (JP) and
the United States (US)
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from 1993–1996 in our analysis as the MarketScan
data during this period did not include Medicare data
which represents the bulk of the US population aged
65 and above.
Toyama et al. [7] estimated the HZ incidence from the
number of subjects that presented a new case of HZ
who subsequently visited one of the 39 dermatology
clinics and the dermatology departments of seven gen-
eral hospitals belonging to the Miyazaki Dermatologic
Society over a period of 10 years (1997–2006). Toyama
et al. state that patients with HZ in Japan primarily
consult dermatology clinics rather than practitioners of
family medicine and, thus, the surveillance system cov-
ered nearly all the patients with HZ in the prefecture.
HZ incidence was presented for the overall population
segregated by age and gender.
MacIntyre et al. [4] presented the age specific HZ inci-
dence based on the number of prescriptions of antivirals
specific for the treatment of HZ. HZ incidence in the
overall population was estimated from the number of
antiviral prescriptions for HZ by adjusting the age
specific numbers of prescriptions with the estimated
proportion of new zoster cases that were prescribed
direct-acting antivirals during the corresponding periods,
derived from analyses of the Bettering the Evaluation
and Care of Health (BEACH) database. The BEACH
database is cross-sectional paper-based data collection of
a nationally representative sample of general practi-
tioners in Australia [4].Table 1 HZ incidence (per 1,000 persons) in the Australia, Japan and
1997 1998 1999 2000 2001 2002
Leung, 2011 (United States) [6] 7.01 7.42 7.80 8.16 8.94 7.73
MacIntyre, 2015 (Australia) [4]
Toyama, 2009 (Japan) [7] 6.19 6.57 7.10 7.06 7.33 7.00Yawn et al. estimated the HZ-attributable healthcare
costs (in 2006 US dollars) for all patients with incident
cases of HZ among residents of Olmsted County,
Minnesota in the US [23]. To estimate the projected
healthcare economic burden arising from HZ in those
aged 65 and above for the US in 2030, we used the
corresponding population estimates for the US and the
projected HZ incidence obtained using scenario 1 (men-
tioned earlier). The 2006 US dollar healthcare costs were
adjusted for the mid-year 2030 values by extrapolating
the monthly US consumer price index for medical care
trends from 2005–2015 using a linear best-fit [24]. It is
assumed that the proportion of incident HZ cases that
go on to develop sequelae (PHN and other non-pain
complications) [3] remain constant over the time period
of analysis.
All analyses were performed using Microsoft Excel.
Results
HZ Incidence
The incidence data from the three countries showed an
average annual increase of between 2.35% [7] (Japan;
Toyama et al.) and 3.74% [6] (US; Leung et al.) over the
corresponding study time periods (Fig. 1).
The incidence data for the three selected studies are
shown below in Table 1.
Demographics
The population projections for the ≥65 age cohort ob-
tained from the United Nations data source are shown
in Table 2. The elderly population for the US, Japan and
Australia are expected to increase by 55, 10 and 53% re-
spectively by the year 2030 compared to the levels in
2015. In 2001, 12.3% of the entire US population were
aged ≥65; in 2030, that proportion is estimated to rise to
20.7%; a 68% increase over a period of 30 years. A simi-
lar trend is observed for Australia (Table 2). Japan, how-
ever, shows a much higher proportion of older adults
(17.7% aged 65 and above in 2001) and the proportion is
estimated to increase by 71.8% in 2030 to reach 30.4% of
the total population. The proportion of the population
aged ≥80 is expected to increase by 223 to 12.7% of the
entire Japanese population in 2030.
Estimated incident HZ cases
In the first scenario, the number of incident HZ cases in
the population aged ≥65 in the US is expected tothe United States
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
9.06 9.04 9.93 10.11
8.36 8.72 8.66 8.66 8.85 9.21 9.64 9.80 10.55 11.04
7.25 7.61 8.05 7.81
Table 2 Population estimates for Australia, Japan and the United States
United States Japan Australia
Age group Population % of total population Population % of total population Population % of total population
2001 All 285,796,198 125,974,298 19,308,681
>65 35,142,215 12.3 22,301,302 17.7 2,402,399 12.4
>80 9,411,233 3.3 4,929,411 3.9 567,071 2.9
2015 All 321,773,631 126,573,481 23,968,973
>65 47,577,672 14.8 33,342,003 26.3 3,606,102 15.0
>80 12,100,608 3.8 9,821,543 7.8 930,769 3.9
2030 All 355,764,967 120,127,264 28,481,570
>65 73,558,551 20.7 36,551,621 30.4 5,524,027 19.4
>80 19,378,487 5.4 15,196,468 12.7 1,618,736 5.7
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2030) while the related increases in Japan and Australia
are +176% (158,616 to 437,867) and +376% (18,105 to
86,268) respectively (Table 3).
In second scenario, the percentage increases from
2001 to 2030 for the US, Japan and Australia are +150%
(293,785 to 733,629), +83% (158,616 to 290,641) and
+223% (18,105 to 58,561) respectively (Table 3 and
Figs. 2, 3 and 4).
Estimated healthcare burden
HZ represents a significant burden each year to the
healthcare system [23]. Yawn et al. estimated the annual
HZ-related costs for US population to be around 1.1
Billion (B) US$. By adjusting the 2006 US$ values pre-
sented in the study to the projected 2030 US$ values (by
extrapolating the published medical care cost index from
January 2005 to December 2014 up to June 2030) [24],
and combining it with the projected US population and
HZ incidence for 2030, we estimated annual cost of HZ-
related cases (assuming no vaccination) in the ≥65 age
cohort to be approximately 4.74 Billion (B) US$
(Table 4).
The complications of HZ (including PHN and other
non-pain complications), which manifest in nearly 20–
25% of HZ cases, cost nearly three times as much as an
uncomplicated case of HZ [23]. Of the estimated 4.74B
US$ HZ-associated costs in the US in 2030 in theTable 3 Projected annual incident cases of HZ in Australia, Japan an
United States
2001 2015 203
Scenario 1 Projected Incidence (per 1,000) 8.36 12.88 17.7
HZ cases in ≥65 years old 293,785 612,692 1,30
Scenario 2 Projected Incidence (per 1,000) 8.36 9.97 9.97
HZ cases ≥65 years old 293,785 474,511 733
Scenario 1: linear extrapolation of HZ incidence trends observed during study perio
carried forward) HZ: Herpes Zoster≥65 years old, 62% of the costs (2.94B US$) arise from the
treatment of PHN and other complications (Table 4).
Since the risk of developing HZ-associated complications
(PHN and other non-pain complications) increases with
age [3], the trend of the increasing proportion of the ≥80
population, especially in countries like Japan, is expected
to further increase the economic burden of HZ.Discussion
Considering the simultaneous projected increase in
the elderly population and the increase in HZ inci-
dence, countries like the US, Japan and Australia are
expected to see an increase of 110 and 213% in HZ
cases between 2015 and 2030 in the ≥65 years old.
The increase in both HZ incidence and the aging
population is expected to be a global trend and thus
the economic burden of HZ on healthcare systems is
expected to be a global phenomenon as well.
There are limitations to the methodological approach
undertaken in this study. This study used two scenarios
to model and to project the temporal trend of HZ
incidence in three chosen countries: a linear best-fit ex-
trapolation of the reported annual incidence and a last
observation carried forward method. A more rigorous
approach would be to employ a time-series analysis and
present the 95% confidence interval estimates for the
predicted incidence in 2030. A Holt-Winters doubled the United States in 2030
Japan Australia
0 2001 2015 2030 2001 2015 2030
2 7.11 9.46 11.98 7.54 11.44 15.62
3,328 158,616 315,482 437,867 18,105 41,243 86,268
7.11 7.95 7.95 7.54 10.60 10.60
,629 158,616 265,120 290,641 18,105 38,229 58,561
































































AU Population HZ Cases (Scenario 1) HZ Cases (Scenario 2)
Fig. 2 Population and HZ incident cases estimates up to 2030 for





























































United States of America
US Population HZ Cases (Scenario 1) HZ Cases (Scenario 2)
Fig. 4 Population and HZ incident cases estimates up to 2030 for
the United States (YoA: Years of Age, HZ: Herpes Zoster; JP: Japan)
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gave an estimate of HZ incidence similar to the inci-
dence estimates obtained using the linear best-fit
method we used. By using the two above-mentioned sce-
narios we feel that we present the range of possible out-
comes of HZ incidence in the corresponding countries.
Another limitation is that we used only one set of data
for each country to predict HZ burden. Thus, the esti-
mates may be potentially biased based on the study de-
sign and assumptions used in the corresponding studies.
An alternative to this approach would have been to use
meta-regression on the data obtained from all the stud-
ies. However, this would require a greater level of data
(e.g. up to patent-level data in some cases) to factor
out the variates present in the studies. Such an exer-
cise would have to be undertaken to obtain a more
accurate prediction of incidence. A better understand-
































































JP Population HZ Cases (Scenario 1) HZ Cases (Scenario 2)
Fig. 3 Population and HZ incident cases estimates up to 2030 for
Japan (YoA: Years of Age, HZ: Herpes Zoster; JP: Japan)incidence will also have to be studied to model
trends. Various hypotheses have been postulated, but
no consensus has been reached.
One of the reasons cited for this increase is the intro-
duction of the varicella vaccination; [13] repeated expos-
ure of the population to naturally circulating is thought to
limit the occurrence of HZ through exogenous boosting
of immunity to the varicella virus. However, both Hales
et al. [11] and Russell et al. [5] have shown that the in-
creasing trend of HZ incidence was evident even before
the introduction of varicella vaccination in the US and
Canada, respectively. The increased HZ incidence is also
evident in countries without varicella vaccination pro-
grams or before the introduction of the vaccine [4, 7]. An
assessment of impact modelling studies from various
countries predicted that mass varicella vaccinations are
expected to increase HZ incidence for approximately
50 years post-introduction of the vaccine [25]. However,
real world evidence and modelling of the impact of vari-
cella vaccination on HZ incidence is conflicting and fur-
ther research is necessary to obtain a robust assessment.
In addition to the introduction of the public varicella
vaccination programs, various other hypothetical factors
have been attributed to the increase in HZ incidence
such as, the aging population and associated chronic
conditions and the increased prevalence of immunosup-
pressive conditions and treatments. Several studies, from
various countries, suggest that age-specific HZ incidence
has been increasing, i.e. the increasing incidence is
observed across all age-groups [5, 11]. Also, a case-
control study performed in the US [26] found that while
the risk of HZ does increase with increasing number of
chronic conditions, they do not ‘substantially explain’
why certain people go on to develop HZ.
Immunosenescence brought on by aging has been
demonstrated to be associated with the reactivation of
Table 4 Estimated HZ-related healthcare cost burden for the ≥65 in the United States in 2030
2005 2030
Cost/Case Cases ('000 s) Total
HZ Costs (US$)
Cost/Case Cases ('000 s) Total
HZ Costs (US$)
All HZ $1,851 339 $627,773,213 $3,640 1,303 $4,743,559,326
HZ with PHN or Complications $4,869 80 $389,153,306 $9,601 306 $2,937,397,732
HZ Herpes Zoster, PHN Post-herpetic Neuralgia, US\ United States dollar
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[14]. However, Toyama et al. [7] found that the increase
in HZ incidence was higher than the increase in the
percentage of the older population. Increases in HZ inci-
dence have also been observed across all age groups. It
has been demonstrated that the risk of HZ is higher in
subjects with immunosuppressive conditions or treat-
ments. However, Leung et al. [6] found that the increase
in HZ incidence was present in the ‘healthy’ population
which excluded subjects that had any of the 200 identi-
fied immunosuppressive conditions or treatments.
The increasing trend of HZ incidence may also be due
to changes in other risk factors previously identified for
HZ, e.g. increasing physical limitation or psychological
stress [14, 27]. Increases could also be attributed to
better diagnosis through improved access to healthcare
and public awareness. This increasing trend along with
the concurrent aging of the population is expected to
further strain healthcare budgets. The aging population
coupled with low birth rates in many countries will also
result in a decline in the proportion of the working-age
population [16]. The ratios of the working working-age
population (15–64 years old) to the older age group (65
and above) in the US in 2001 was 5.4 and is estimated to
fall to 3.9 in 2020. A similar trend is observed for
Australia and the corresponding ratios in Japan are 3.8
in 2001 to 2.1 in 2020.
A live attenuated Oka VZV vaccine which is licensed
in various countries was shown to reduce HZ incidence
by 51.1% (95% confidence interval, 44.2–57.6) [28].
However, vaccine efficacy was shown to reduce with age
with the efficacy against HZ incidence dropping to
37.6% in those aged ≥70 [28]. Recent results of a phase
III trial of an adjuvanted HZ subunit vaccine have dem-
onstrated a substantial improvement in vaccine efficacy
in the elderly with an efficacy of 97.2 (95% confidence
interval, 93.7–99.0) in subjects ≥50 years of age [29] and
91.3% (95% confidence interval, 86.8–94.5) in subjects
≥70 years of age [30]. The two vaccines could help
reduce the future global burden of HZ on the elderly.Conclusion
Due to the aging of the global population, a dramatic in-
crease in the number of people suffering from HZ isexpected over the next few decades unless more effective
preventative action is taken.
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